WASHINGTON – One of the first big stories at TCT 2016 was the report of three-year data from the Absorb II study of the Absorb GT1 bioresorbable vascular scaffold system by Abbott Vascular, of Temecula, Calif., which indicated a higher rate of infarct than was seen in the control arm using the company's Xience drug-eluting stent. Read More
